Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
- Written by PR Newswire
![]() |
– New findings demonstrate a 72% HI-E response rate at Week 16 with meaningful hemoglobin improvement –– Strong activity observed across ESA-refractory and ESA-intolerant patients, and across mutation and morphology subtypes –– Favorable safety profile with no treatment-related serious adverse events –
LEHI, Utah,...















